Unknown

Dataset Information

0

Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC.

ABSTRACT: Hepatocellular carcinoma (HCC) is a major type of liver cancer caused by the hepatitis B and C viruses, alcohol and exposure to aflatoxin. For HCC treatment, anticancer drugs have been widely used, but drug resistance in advanced HCC is an important problem, resulting in a continuous need for novel therapeutic targets. Therefore, in this study, we established a screening pipeline based on RNA-seq to screen novel therapeutic/prognostic targets in HCC and identified PRMT1 (Protein Arginine Methyltransferase 1). In the prognostic analysis, the overexpression of PRMT1 was clearly associated with poor prognosis in a number of HCC patient cohorts. Moreover, after PRMT1 knockdown, HCC cell lines exhibited cell growth and spheroid formation suppression, an increase in Sub-G1 cells by FACS analysis, and enrichment of the cell cycle pathway via functional enrichment analysis. With these results, we demonstrated that PRMT1 could be a novel prognostic marker and therapeutic target for HCC therapy.

SUBMITTER: Ryu JW 

PROVIDER: S-EPMC5777784 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC.

Ryu Jea-Woon JW   Kim Seon-Kyu SK   Son Mi-Young MY   Jeon Su-Jin SJ   Oh Jung-Hwa JH   Lim Jung Hwa JH   Cho Sunwha S   Jung Cho-Rok CR   Hamamoto Ryuji R   Kim Dae-Soo DS   Cho Hyun-Soo HS  

Oncotarget 20171214 70

Hepatocellular carcinoma (HCC) is a major type of liver cancer caused by the hepatitis B and C viruses, alcohol and exposure to aflatoxin. For HCC treatment, anticancer drugs have been widely used, but drug resistance in advanced HCC is an important problem, resulting in a continuous need for novel therapeutic targets. Therefore, in this study, we established a screening pipeline based on RNA-seq to screen novel therapeutic/prognostic targets in HCC and identified PRMT1 (Protein Arginine Methylt  ...[more]

Similar Datasets

Unknown Serum exosomal miR-638 is a prognostic marker of HCC via downregulation of VE-cadherin and ZO-1 of endothelial cells.
| S-EPMC7935782 | biostudies-literature
Unknown INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT.
| S-EPMC6790406 | biostudies-literature
Unknown Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
| S-EPMC4741924 | biostudies-literature
Unknown SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC.
| S-EPMC7991385 | biostudies-literature
Unknown lnc-MAP3K13-7:1 Inhibits Ovarian GC Proliferation in PCOS via DNMT1 Downregulation-Mediated CDKN1A Promoter Hypomethylation.
| S-EPMC7934583 | biostudies-literature
Unknown TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer.
| S-EPMC3878622 | biostudies-literature
Unknown COPB2: A Novel Prognostic Biomarker That Affects Progression of HCC.
| S-EPMC8007342 | biostudies-literature
Unknown Cul4B is a novel prognostic marker in cholangiocarcinoma.
| S-EPMC5542034 | biostudies-other
Unknown Novel copper complex CTB regulates methionine cycle induced TERT hypomethylation to promote HCC cells senescence via mitochondrial SLC25A26.
| S-EPMC7548283 | biostudies-literature
Unknown The methyltransferase PRMT1 regulates γ-globin translation.
| S-EPMC7966866 | biostudies-literature